DexCom Inc (DXCM)
DexCom, Inc. is a healthcare equipment company focused on developing and commercializing continuous glucose monitoring systems used in diabetes and metabolic health management. Its product portfolio includes the Dexcom G7 and G7 15 Day integrated CGM systems, the Dexcom G6, Dexcom ONE+ for diabetes treatment decisions without routine fingerstick testing, and Stelo, a biosensor for adults with prediabetes and type 2 diabetes who do not use insulin. The company also provides Dexcom Share and the Dexcom Follow application for remote glucose monitoring. DexCom markets its products directly to endocrinologists, physicians, and diabetes educators. Incorporated in 1999, the company is headquartered in San Diego, California, and its common stock trades on the NASDAQ under the symbol DXCM.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DXCM
|
—
|
—
|
—
|
$85.75
|
14.7% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
31.0x
|
9.7x
|
6.0x
|
29.207 B
|
27.783 B
|
4.5%
|
99.7%
|
7.0
|
—
|
153.6%
|
